OKUR — Onkure Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Onkure Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -39.8 | -52 | -77.4 | -52.7 | -59.5 |
| Depreciation | |||||
| Non-Cash Items | 4.54 | 3.55 | 1.32 | 5.05 | 12 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.8 | 0.959 | 12.2 | -3.95 | -4.78 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -38 | -47.4 | -63.7 | -51.1 | -51.8 |
| Capital Expenditures | -0.198 | -0.346 | -0.221 | -0.052 | -0.046 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -23.2 | -57.5 | 10.7 | 15.9 | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -23.4 | -57.8 | 10.5 | 15.9 | -0.046 |
| Financing Cash Flow Items | — | — | — | 55.5 | -0.077 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 132 | 0.471 | 60.9 | 116 | 0.163 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 71 | -105 | 7.71 | 80.9 | -51.7 |